OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press9410.17650/1818-8346-2011-6-3-82-93LECTURESЛЕКЦИИ ДЛЯ ВРАЧЕЙMyeloid hematological malignanciesГемобластозы миелоидного происхожденияDomninskyD. A.ДомнинскийД. А.Russian FederationD7777777@yandex.ruFederal Research Center of Pediatric Hematology, Oncology and ImmunologyФГБУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздравсоцразвития России2308201163829323072014230720142011https://oncohematology.abvpress.ru/ongm/article/view/94
.
.
1. Vardiman J., Thiele J., Arber D. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–51.Vardiman J., Thiele J., Arber D. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–51.2. Tefferi A., Gilliland G. Oncogenes in myeloproliferative disorders. Cell Cycle 2007;6:550–66.Tefferi A., Gilliland G. Oncogenes in myeloproliferative disorders. Cell Cycle 2007;6:550–66.3. Noble M., Endicott J., Johnson L. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800–5.Noble M., Endicott J., Johnson L. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800–5.4. Lemmon M., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117–34.Lemmon M., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117–34.5. Toffalini F., Demoulin J.B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010;116:2429–37.Toffalini F., Demoulin J.B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010;116:2429–37.6. Jura N., Zhang X., Endres N. et al. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 2011;42:9–22.Jura N., Zhang X., Endres N. et al. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 2011;42:9–22.7. Taylor S., Kornev A. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 2011;36:65–77.Taylor S., Kornev A. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 2011;36:65–77.8. Matsumura I., Mizuki M., Kanakura Y. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. Cancer Sci 2008;99:479–85.Matsumura I., Mizuki M., Kanakura Y. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. Cancer Sci 2008;99:479–85.9. Griffith J., Black J., Faerman C. et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004;13:169–78.Griffith J., Black J., Faerman C. et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004;13:169–78.10. Hubbard S. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:464–71.Hubbard S. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:464–71.11. Reindl C., Spiekermann K. From kinases to cancer. Leakiness, loss of autoinhibition and leukemia. Cell Cycle 2006;5:599–602.Reindl C., Spiekermann K. From kinases to cancer. Leakiness, loss of autoinhibition and leukemia. Cell Cycle 2006;5:599–602.12. Jatiani1 S., Baker S., Silverman L., Reddy P. JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 2010;1:979–93.Jatiani1 S., Baker S., Silverman L., Reddy P. JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 2010;1:979–93.13. Chalandon Y., Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005;90:949–68.Chalandon Y., Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005;90:949–68.14. Krause D., van Etten R. Tyrosine kinases as targets for cancer therapy. New Engl J Med 2005;353:172–87.Krause D., van Etten R. Tyrosine kinases as targets for cancer therapy. New Engl J Med 2005;353:172–87.15. Bain B. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica 2010;95:696–8.Bain B. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica 2010;95:696–8.16. Gotlib J., Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008;22:1999–2010.Gotlib J., Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008;22:1999–2010.17. Schwartz R. A molecular star in the wars against cancer. New Engl J Med 2002;347:462–3.Schwartz R. A molecular star in the wars against cancer. New Engl J Med 2002;347:462–3.18. Curtis C., Grand F., Musto P. et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Brit J Haematology 2007;138:77–81.Curtis C., Grand F., Musto P. et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Brit J Haematology 2007;138:77–81.19. Eswaran J., Knapp S. Insights into protein kinase regulation and inhibition by large scale structural comparison. BiochimBiophys Acta 2010;1804:429–32.Eswaran J., Knapp S. Insights into protein kinase regulation and inhibition by large scale structural comparison. BiochimBiophys Acta 2010;1804:429–32.20. Sugimoto Y., Muramatsu H., Makishima H. et al. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Brit J Haematol 2010;150:83–7.Sugimoto Y., Muramatsu H., Makishima H. et al. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Brit J Haematol 2010;150:83–7.21. Chan R., Feng G.S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007;109:862–7.Chan R., Feng G.S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007;109:862–7.22. Matozaki T., Murata Y., Saito Y. et al. Protein tyrosine phosphatase SHP-2: a protooncogene product that promotes Ras activation. Cancer Sci 2009;100:1786–93.Matozaki T., Murata Y., Saito Y. et al. Protein tyrosine phosphatase SHP-2: a protooncogene product that promotes Ras activation. Cancer Sci 2009;100:1786–93.23. Ostman A., Hellberg C., Bohmer F. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006;6:307–20.Ostman A., Hellberg C., Bohmer F. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006;6:307–20.24. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Brit J Cancer 2006;94:179–83.Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Brit J Cancer 2006;94:179–83.25. Krivtsov A., Armstrong S. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823–33.Krivtsov A., Armstrong S. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823–33.26. Slany R. The molecular biology of mixed lineage leukemia. Haematologica 2009;94:984–93.Slany R. The molecular biology of mixed lineage leukemia. Haematologica 2009;94:984–93.27. Marschalek R. Mixed lineage leukemia: roles in human malignancies and potential therapy. FEBS J 2010;277:1822–31.Marschalek R. Mixed lineage leukemia: roles in human malignancies and potential therapy. FEBS J 2010;277:1822–31.28. Cosgrove M., Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J 2010;277:1832–42.Cosgrove M., Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J 2010;277:1832–42.29. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Brit J Haematology 2011;152:141–54.Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Brit J Haematology 2011;152:141–54.30. Mohan M., Lin C., Guest E., Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010;10:721–8.Mohan M., Lin C., Guest E., Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010;10:721–8.31. Basecke J., Whelan J., Griesinger F., Bertrand F. The MLL partial tandem duplication in acute myeloid leukaemia. Brit J Haematology 2006;135:438–49.Basecke J., Whelan J., Griesinger F., Bertrand F. The MLL partial tandem duplication in acute myeloid leukaemia. Brit J Haematology 2006;135:438–49.32. Greaves M. Childhood leukaemia. Molecular genetics provide exciting new insights into the pathogenesis of childhood leukaemia. Brit Med J 2002;324:283–7.Greaves M. Childhood leukaemia. Molecular genetics provide exciting new insights into the pathogenesis of childhood leukaemia. Brit Med J 2002;324:283–7.33. Wiemels J. Chromosomal translocations in childhood leukemia: natural history, mechanisms and epidemiology. J Natl Cancer Inst Monographs 2008;39:87–90.Wiemels J. Chromosomal translocations in childhood leukemia: natural history, mechanisms and epidemiology. J Natl Cancer Inst Monographs 2008;39:87–90.34. Meyer C., Kowarz E., Hofman J. et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009;23:1490–9.Meyer C., Kowarz E., Hofman J. et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009;23:1490–9.35. Balgobind B., Raimondi S., Harbott J. et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009;114:2489–96.Balgobind B., Raimondi S., Harbott J. et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009;114:2489–96.36. Liu H., Cheng E., Hsieh J. MLL fusions. Pathways to leukemia. Cancer Biol & Therapy 2009;8:1204–11.Liu H., Cheng E., Hsieh J. MLL fusions. Pathways to leukemia. Cancer Biol & Therapy 2009;8:1204–11.37. Frohling S., Dohner H. Chromosomal abnormalities in cancer. New Engl J Med 2008;359:722–34Frohling S., Dohner H. Chromosomal abnormalities in cancer. New Engl J Med 2008;359:722–34